Cleerly ISCHEMIA vs Eko Low Ejection Fraction Tool (ELEFT)
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a detailed, non-invasive assessment of coronary artery disease, including vessel-level ischemia likelihood and comprehensive plaque characterization, based on a CCTA scan. This tool is ideal for refining diagnosis and personalizing treatment plans for patients with suspected or known coronary artery disease, offering insights beyond simple stenosis detection.
View Cleerly ISCHEMIA →Choose Eko Low Ejection Fraction Tool (ELEFT) if…
Choose Eko Low Ejection Fraction Tool (ELEFT) if you need a rapid, non-invasive screening tool for early detection of low ejection fraction during routine physical examinations. This AI algorithm, integrated with a digital stethoscope, is best suited for primary care or general clinical settings to quickly identify patients at risk for heart failure, prompting timely referral for further diagnostic evaluation.
View Eko Low Ejection Fraction Tool (ELEFT) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Deployment | Web-based solution | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Low Ejection Fraction Tool (ELEFT)Eko Low Ejection Fraction Tool (ELEFT) integrates directly with Eko digital stethoscopes for use during routine physical exams, providing rapid results in approximately 15 seconds, making it highly accessible and efficient for point-of-care screening. Cleerly ISCHEMIA, while offering comprehensive interactive web-based reports, is part of a more involved CCTA imaging workflow and requires data transfer via a proxy, which might introduce more setup complexity for the end-user clinician.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA offers a more comprehensive and granular assessment of coronary artery disease, including non-invasive fractional flow reserve (FFR) estimation, vessel-level ischemia likelihood, and detailed coronary plaque characterization. This directly informs personalized diagnosis and treatment planning for heart disease. While ELEFT provides valuable early detection of low ejection fraction, Cleerly's depth of diagnostic information offers a broader clinical impact for managing complex cardiac conditions.
Pricing & Value
TieBoth Cleerly ISCHEMIA and Eko Low Ejection Fraction Tool (ELEFT) have opaque pricing models, requiring direct contact for specific details. Neither tool provides public information on pricing structures or costs, making it impossible to compare their cost-effectiveness or overall value proposition.
Enterprise Readiness
TieBoth tools are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements, fulfilling critical requirements for enterprise adoption in healthcare. Cleerly ISCHEMIA provides API integration with PowerScribe and secure data transfer via a proxy, while ELEFT is explicitly part of Eko's SENSORAu2122 enterprise platform and leverages cloud-based infrastructure, indicating comparable readiness for large-scale deployment.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates a higher degree of innovation by leveraging AI to perform non-invasive fractional flow reserve (FFR) estimation and detailed coronary plaque characterization from CCTA scans, providing insights traditionally requiring more invasive procedures. While ELEFT's integration of AI into a stethoscope for real-time heart failure screening is innovative for point-of-care diagnostics, Cleerly's advanced analytical capabilities push the boundaries of non-invasive cardiac imaging and diagnosis.
Support & Docs
Eko Low Ejection Fraction Tool (ELEFT)Eko Health provides a dedicated online Help Center with FAQs, troubleshooting guides, and articles, along with direct contact options for support via phone and email, indicating a more comprehensive and accessible support infrastructure. Cleerly's public information primarily offers general contact forms and resources like white papers, without explicit details on technical support channels or user documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Tool Name | Cleerly ISCHEMIA | Eko Low Ejection Fraction Tool (ELEFT) |
| Primary Use Case | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. |
| Key Technology/Input | AI-enabled CCTA analysis | Integrates with FDA-cleared Eko digital stethoscopes; Analyzes ECG and heart sound recordings |
| Output/Detection | Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment, 3D digital models of coronary arteries, Comprehensive interactive web-based reports. | AI-powered low ejection fraction detection; Provides results in approximately 15 seconds; Aids in early identification of heart failure risk. |
| Specialties | Cardiology, Radiology | Cardiology, Family Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and Eko Low Ejection Fraction Tool (ELEFT).
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or Eko Low Ejection Fraction Tool (ELEFT)
Backers
Who funded each tool's parent company.